

# **Efficacy, safety, and tolerability of remibrutinib (LOU064) in CSU patients Study design of Phase 3b extension trial**

*M. Maurer, A. Giménez-Arnau, S. Saini, M. Lebwohl, G. Sussman, M. Hide, K. Lheritier, A. Zharkov, S. Bhat, L. Wei, ED. Martzloff, S. Haemmerle*

***Please click [HERE](#) to subscribe to news alerts of the Novartis Urticaria Knowledge Center and to receive an email notification once the publication is available***

***Or use this [LINK](#) to access the abstract after 11<sup>th</sup> June 2023, once it is available at the congress website***